Atrium Therapeutics, Inc.

RNA • Biotechnology

$14.19

▼ -0.41 (-2.81%)

Current price

EarningsLatest report: Mar 31, 2026

WEAK PROFILEWeakConfidence: 32%

Quantitative profile — not an investment recommendation.

Quantitative profile — not an investment recommendation.Methodology

Analysis thesis: Weak historical ratio profile. The current evidence does not support a favorable risk/reward view.

Market Cap

$242.73M

Growth

—

Cash Flow

—

Trend

Limited data

Evidence

Manageable debt level · 0.02Healthy liquidity · 6.53Weak profitability

Financial data as of: Mar 31, 2026, 12:00 AM UTCLast earnings update: May 14, 2026, 12:00 AM UTCLast profile update: Aug 14, 2026, 12:19 PM UTC

Company Snapshot

Key valuation, quality, financial strength, momentum and analyst data.

Price$14.19

Change-2.81%

Shares Out17.11M

Market Cap$242.73M

Enterprise Value$-22.44M

52W Range11.13 - 16.77

Beta0.37

P/B1.04

Gross Margin100.00%

Oper. Margin-4.13%

Profit Margin-4.12%

Debt/Eq0.02

Price$14.19

Change-2.81%

Shares Out17.11M

Market Cap$242.73M

Enterprise Value$-22.44M

52W Range11.13 - 16.77

Beta0.37

P/B1.04

Gross Margin100.00%

Oper. Margin-4.13%

Profit Margin-4.12%

Debt/Eq0.02

Current Ratio6.53

Quick Ratio6.53

Target$25.00

Target Upside76.18%

Target Median$25.00

Target Range25.00 - 25.00

Volume101.55K

Avg Volume201.59K

EPS Surprise0.08

Investment DNA

How strong this company looks for long-term investors

33

out of 100

Business Quality

Margins, moat, returns

30/100

Financial Strength

Debt, cash, stability

76/100

Growth Potential

Revenue and expansion

50/100

Price Attractiveness

Cheap or expensive today

69/100

Why this score▼

Manageable debt level · 0.02Healthy liquidity · 6.53Weak profitability

Analyst view

Analyst sentiment and price target

RNA

Analyst sentiment

Based on 16 analyst votes · 2026-09-05

75/100

Bullish

Bullish

8

Hold

8

Bearish

0

Price Target

2026-08-14

Low

$25.00

Mean

$25.00

Median

$25.00

High

$25.00

Company Overview

IPO: 2/27/2026

Industry: Biotechnology

P/B i: 1.04

Debt / Equity i: 0.02

Operating Margin: -412.58%

Net Margin: -411.88%

ROE i: -

ROIC: -

Financial Health

Score15 / 20

Debt / Equity: 0.02

Current Ratio: 6.53

Quick Ratio: 6.53

Status: Good

🧾

No insider activity

No recent insider transactions available.

About the Company

Atrium Therapeutics, Inc.

Atrium Therapeutics, Inc. is a biopharmaceutical company dedicated to revolutionizing the treatment of cardiomyopathies by delivering innovative ribonucleic acid (RNA) therapeutics directly to the heart. Their development-stage portfolio currently includes ATR 1072, a siRNA-based therapy targeting the PRKAG2 gene for the treatment of PRKAG2 syndrome, and ATR 1086, another siRNA therapy aimed at the PLN gene to address PLN cardiomyopathy. The company is also actively developing a wider range of pipeline candidates designed to combat various genetic and cardiac diseases. Founded in 2025, Atrium Therapeutics is based in San Diego, California.

📰

No info available now

Check back later.

Latest news

9

Atrium Therapeutics to Participate in Upcoming Investor Conferences

SAN DIEGO, Sept. 2, 2026 /PRNewswire/ -- Atrium Therapeutics, Inc. (Nasdaq: RNA), a biopharmaceutical company advancing precision cardiology by developing RNA therapeutics targeted to the heart, today announced that it will participate in upcoming investor conferences in September.

Atrium Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

SAN DIEGO, Aug. 20, 2026 /PRNewswire/ -- Atrium Therapeutics, Inc. (Nasdaq: RNA) (the "Company") today announced it awarded inducement grants on August 20, 2026 under the Company's 2026 Employment Inducement Incentive Award Plan (the "2026 Inducement Plan") as a material inducement to the employment of one non-executive individual newly hired by the Company. The employee received, in the aggregate, non-qualified stock options to purchase 11,000 shares of the Company's common stock, par value $0.001 per share, with an exercise price of $13.48 per share, the closing price of the Company's common stock as reported by Nasdaq on the grant date, 25% of which will vest and become exercisable on the first anniversary of the grant date, and the remainder of which will vest in 36 substantially equal installments each month thereafter, subject to the employee's continued service with the Company through each applicable vesting date; and restricted stock units for an aggregate of 5,500 shares of the Company's common stock, 25% of which will vest on the first anniversary of the grant date, and the remainder of which will vest in 3 substantially equal installments each year thereafter, subject to the employee's continued service with the Company through each applicable vesting date (collectively, the "Awards").

Atrium Therapeutics Reports Second Quarter 2026 Financial Results

-- IND clearance for ATR 1072 and launch of Corventis Phase 1/2 trial in PRKAG2 syndrome -- -- Achieved second milestone payment under global cardiovascular collaboration with Bristol Myers Squibb -- SAN DIEGO, Aug. 13, 2026 /PRNewswire/ -- Atrium Therapeutics, Inc. (Nasdaq: RNA) ("Atrium," "Atrium Therapeutics," or the "Company"), a biopharmaceutical company advancing precision cardiology by developing RNA therapeutics targeted to the heart, today reported financial results for the second quarter ended June 30, 2026, and highlighted recent corporate progress including FDA clearance of its Investigational New Drug (IND) application for ATR 1072 and continued achievements under its collaboration with Bristol Myers Squibb (BMS). "Our team continues to execute well, achieving FDA clearance of our IND for ATR 1072 and launching Corventis — Atrium's first Phase 1/2 trial and the first clinical study to evaluate a potential disease-modifying treatment for people living with PRKAG2 syndrome," said Kathleen Gallagher, President and Chief Executive Officer of Atrium Therapeutics.

Atrium Therapeutics Earns $15 Million Milestone Payment from Bristol Myers Squibb Under Global Cardiovascular Collaboration

SAN DIEGO, Aug. 13, 2026 /PRNewswire/ -- Atrium Therapeutics, Inc. (Nasdaq: RNA) ("Atrium," "Atrium Therapeutics" or the "Company"), a biopharmaceutical company dedicated to delivering RNA therapeutics to the heart, today announced it has earned another $15 million milestone payment from Bristol Myers Squibb (NYSE: BMY) based on the successful delivery of a lead compound targeting an undisclosed cardiology indication under the Company's ongoing collaboration. "Atrium's vision is to deliver treatments that address the underlying cause of serious heart disease, including rare genetic cardiomyopathies," said Kathleen Gallagher, President and CEO of Atrium Therapeutics.

Here Are Thursday’s Top Wall Street Analyst Research Calls: AppLovin, Charles River, Global Payments, HubSpot, Insulet Corporation, Roper Technologies, Sabra Health Care, Western Digital, Zillow Group, and More

Wall Street analysts made some dramatic moves on Thursday, slashing price targets by double digits on several high-profile names while upgrading others to buy. Find out which stocks got the most surprising treatment before the opening bell.

Earnings Surprises

Period	Estimate	Actual	Surprise
2026-05-14	-1.05	-0.97	0.08
2026-02-26	-1.24	-0.61	0.63